(Q37773257)

22 August 2017

1 reference

title

Drug-mediated and cellular immunotherapy in multiple myeloma (English)

1 reference

22 August 2017

1 reference

David S Ritchie

1

1 reference

22 August 2017

Hang Quach

series ordinal

2

1 reference

22 August 2017

Kate Fielding

series ordinal

3

1 reference

22 August 2017

Paul Neeson

series ordinal

4

1 reference

22 August 2017

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

2

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

243-255

1 reference

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

22 August 2017

cites work

1 reference

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

Treatment of myeloma: cure vs control

21 January 2018

1 reference

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

21 January 2018

1 reference

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

21 January 2018

1 reference

Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines

21 January 2018

1 reference

Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma

21 January 2018

1 reference

Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells

21 January 2018

1 reference

A fresh look at tumor immunosurveillance and immunotherapy.

21 January 2018

1 reference

Immunodeficiency and immunotherapy in multiple myeloma

21 January 2018

1 reference

Immunoregulatory mechanisms in multiple myeloma

21 January 2018

1 reference

High Th1/Th2 ratio in patients with multiple myeloma.

21 January 2018

1 reference

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma

21 January 2018

1 reference

A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma

21 January 2018

1 reference

Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.

21 January 2018

1 reference

Tregs and rethinking cancer immunotherapy

21 January 2018

1 reference

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo

21 January 2018

1 reference

Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction

21 January 2018

1 reference

Regulatory T cells in cancer

21 January 2018

1 reference

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

Regulatory T cells and multiple myeloma

21 January 2018

1 reference

Dysfunctional T regulatory cells in multiple myeloma

21 January 2018

1 reference

CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets

21 January 2018

1 reference

In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.

21 January 2018

1 reference

Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma

21 January 2018

1 reference

Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo

21 January 2018

1 reference

Endogenous IL-17 contributes to reduced tumor growth and metastasis

21 January 2018

1 reference

IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway

21 January 2018

1 reference

Protumor vs antitumor functions of IL-17.

21 January 2018

1 reference

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

21 January 2018

1 reference

Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4.

21 January 2018

1 reference

Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study

21 January 2018

1 reference

Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo.

21 January 2018

1 reference

Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).

21 January 2018

1 reference

The proteasome inhibitor bortezomib enhances the susceptibility to viral infection

21 January 2018

1 reference

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin

21 January 2018

1 reference

B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice

21 January 2018

1 reference

Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma

21 January 2018

1 reference

Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma

21 January 2018

1 reference

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

21 January 2018

1 reference

Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

21 January 2018

1 reference

Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients

21 January 2018

1 reference

Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions

21 January 2018

1 reference

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

21 January 2018

1 reference

Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates

21 January 2018

1 reference

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

21 January 2018

1 reference

Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives

21 January 2018

1 reference

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

21 January 2018

1 reference

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

21 January 2018

1 reference

A comparison of allografting with autografting for newly diagnosed myeloma

21 January 2018

1 reference

CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT.

21 January 2018

1 reference

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

21 January 2018

1 reference

Anti-myeloma activity of natural killer lymphocytes

21 January 2018

1 reference

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice

21 January 2018

1 reference

A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.

21 January 2018

1 reference

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

21 January 2018

1 reference

Toward an understanding of NKT cell biology: progress and paradoxes

21 January 2018

1 reference

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells

21 January 2018

1 reference

Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation.

21 January 2018

1 reference

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

Antibody-Dependent Killing of Tumor Cells by Polymorphonuclear Leukocytes. Involvement of Oxidative and Nonoxidative Mechanisms23

21 January 2018

1 reference

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

21 January 2018

1 reference

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells

21 January 2018

1 reference

Immunogenic and tolerogenic cell death

21 January 2018

1 reference

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

21 January 2018

1 reference

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

The IKK NF-kappa B system: a treasure trove for drug development

21 January 2018

1 reference

NF-kappaB in the pathogenesis and treatment of multiple myeloma

21 January 2018

1 reference

Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

21 January 2018

1 reference

Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy

21 January 2018

1 reference

Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor

21 January 2018

1 reference

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

21 January 2018

1 reference

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma

21 January 2018

1 reference

Targeted therapies in multiple myeloma

21 January 2018

1 reference

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

21 January 2018

1 reference

Eradication of established tumors in mice by a combination antibody-based therapy

21 January 2018

1 reference

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

21 January 2018

1 reference

Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma

21 January 2018

1 reference

B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors

21 January 2018

1 reference

CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.10.9

1 reference

22 August 2017

1 reference